There is an unmet need for new treatment methods for inflammatory bowel disease (IBD) that 31 can reliably maintain remission without leading to detrimental side effects. Beneficial bacteria 32 have been utilized as an alternative treatment for IBD albeit with low efficacy. We genetically 33 engineered Escherichia coli Nissle 1917 (EcN) to create an anti-inflammatory fibrous matrix in 34 situ. This matrix consists of EcN-produced curli nanofibers displaying trefoil factors (TFFs), 35 known to promote intestinal barrier function and epithelial restitution. We confirmed that 36 engineered EcN was able to secrete the curli-fused TFFs in vitro and in vivo, and was non-37 pathogenic. We observed an enhanced protective effect of engineered EcN against dextran 38 sodium sulfate induced colitis in mice, associated with barrier function reinforcement and 39 immunomodulation. This work sets the foundation for the development of a novel therapeutic 40 platform in which the in situ production of a therapeutic protein matrix from beneficial bacteria 41 can be exploited. 42 90 concentrations of the therapeutic molecule at the site of disease. Indeed, concerns have been 91 raised about the compatibility of this strategy with immunomodulatory biologics, since the 92 mucosal epithelial barrier hinders their trafficking to their target cells in the lamina propria (13, 93 14). Nevertheless, the promise of effective treatments that can be produced cheaply, delivered 94 orally, and minimize systemic side effects has continued to fuel interest in microbes as 95 therapeutics.
PBP8) in order to preclude the possibility of curli fiber expression from native genes 141 confounding our experimental results (24). 142 In order to confirm that curli fibers decorated with TFFs could be produced by EcN, as they can Curli production experiments performed with PBP8 led to similar trends. In some cases, basal 153 expression of the csgA genes was observed without induction ( Figure S1A, B ). We have also 154 confirmed the presence of the displayed TFF3 using similar whole cell ELISA assay ( Engineered curli fibers do not confer pathogenicity to EcN in vitro 165 We had previously demonstrated that the CsgA-TFF3 fusion, when produced by a laboratory 166 strain of E. coli, could bind to mucins and promote mammalian cell migration in an in vitro 167 model with a human colorectal adenocarcinoma cell line (Caco-2) (22) . Before proceeding to in 168 vivo studies, we wanted to confirm that modified curli fiber overproduction did not induce a 169 pathogenic phenotype in PBP8. Therefore, we performed invasion and barrier function assays on 170 Caco-2 cells grown to confluency in transwells. None of the EcN derived strains (i.e. PBPB8 -171 curli genes deleted, PBP8 wt-CsgA -expressing the wild-type CsgA sequence, PBP8 CsgA-172 TFF3 -expressing the CsgA-TFF3 fusion) exhibited increased invasiveness into polarized Caco-173 2 monolayers when compared to unmodified EcN (Figure 3) . Invasion for Caco-2 monolayers 174 was low across all groups in comparison to a positive control, Salmonella typhimurium (SL 175 1344) ( Figure 3A) . Similarly, in a translocation assay in which bacteria were collected from the 176 basolateral chamber of the transwell (26), we observed essentially no translocation of any of the 177 EcN derived strains ( Figure 3B ). We also monitored barrier function in the transwells as a 178 function of bacterial strain. Trans-epithelial electrical resistance (TEER) measurements showed 179 lower reductions TEER values for all of the EcN derived strains compared to S. typhimurium -180 40-50% vs. 70%, respectively ( Figure S2 ). We also tested barrier function in vitro via the 181 translocation of fluorescently labeled dextrans by adding them to the apical chamber of the 182 transwell after 24 hours of incubation with the bacteria (26, 27). We observed almost no 183 translocation for any of the EcN derived strains, while the positive control (S. typhimurium) led 184 to significant translocation of the polymer to the basolateral chamber ( Figure 3C ). While Caco-2 185 cells are a crude mimic of the mucosal epithelium, they are known to respond to exposure to 186 pathogenic bacteria in predictable ways that include the activation of pro-inflammatory signaling 187 cascades and release of cytokines such as IL-8 (26, 28-31). We monitored the response of 188 polarized Caco-2 cells to apical bacterial exposure for 24 hours and found that EcN and the 189 PBP8 variants showed no significant differences in IL-8 production, while S. typhimurium 190 showed a 4-fold increase compared to cells with no bacterial exposure ( Figure 3D ). Overall, the 191 transwell assays indicated that neither PBP8, nor the expression of wt-CsgA or CsgA-TFF3 led 192 to any phenotypes that compromised epithelial integrity compared to unmodified EcN. CFU count of 10 8 -10 9 over the course of the experiment, similar to that of EcN transformed with 205 a pBbB8k plasmid encoding for green fluorescent protein (GFP) as a control ( Figure 4A ). This 206 suggested that wild-type curli fiber overproduction in vivo did not compromise the fitness of the 207 engineered EcN any more than recombinant production of any heterologous intracellular protein.
208
In comparison, EcN CsgA-TFF2 and EcN CsgA-TFF3 concentrations fell over the course of the 209 experiment to ~10 6 -10 7 CFU, suggesting that production of the CsgA-TFF fusions was stressful 210 enough to compromise the colonization ability of EcN in the stringent environment of the mouse gut. We speculate that this may be due to the large size of the TFF fusion domains (34), in 212 addition to their propensity to form internal disulfide bonds that could hinder extracellular 213 export. Indeed, the difference in growth rates between wt-CsgA and CsgA-TFF producing strains 214 is reflected in the in vitro growth rates ( Figure S3 ). We further confirmed the presence of the 215 engineered EcN strains in living animals by visualization of the bacterial luminescence on days 216 2, 6, and 10 after oral administration using an in vivo imaging system (IVIS). As expected, the 217 luminescence of the EcN could be observed in the abdomen of all mice that had received bacteria 218 ( Figure 4B and S4). 
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In addition to the engineered bacteria themselves, we sought to confirm that the 226 engineered curli fibers were being produced in situ. We therefore performed ELISA using an 227 anti-6xHis antibody on homogenized fecal samples obtained 5 days after oral administration. We 228 found that, as expected, only mice that had received curli producing strains (EcN wt-CsgA and 229 EcN CsgA-TFF3) showed signal above background levels ( Figure 4C ). In comparison, EcN 230 producing GFP only showed only background signal. Finally, we used immunohistochemistry at 231 the experimental endpoint to visualize the engineered curli fibers directly in tissue sections of the 232 proximal and distal colon ( Figure 5 ). The curli fibers were probed with a fluorescently labeled 233 anti-6xHis antibody (magenta), while anti-MUC2 (red), anti-E-cadherin (green), and Hoechst (blue) stains were used to visualize the mucins and colonic epithelial cells. We found that due to 235 the fixing and staining protocol, which were designed to preserve the integrity of the intestinal 236 mucins, the Hoechst and E-cadherin antibodies stained not only the colonic cells, but also DNA 
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We examined the protective effects of engineered CsgA-TFF3 produced by PBP8 using 266 female C57BL/6NCrl mice that had been administered 3% DSS over several days to induce 267 colonic inflammation. Pilot experiments with oral administration of PBP8 strains were not very 268 effective in decreasing disease symptoms. However, histological analysis and further literature 269 consultation revealed that DSS induced colitis was most severe in the distal colon, whereas the 270 engineered bacteria resided mostly in the cecum and proximal colon ( Figure S5 ) (24, 37, 38). In 271 order to circumvent this peculiarity of the murine DSS model and investigate the efficacy of our 272 approach, we pivoted to rectal administration of the bacteria so that they could easily co-localize 273 with the affected tissues. Notably, we do not envision that this issue would affect the efficacy of 274 engineered bacteria in other models or in humans, as both oral and rectal deliveries are viable 275 routes of drug administration depending on the patient's disease localization.
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As outlined in Figure 6A , the mice received daily administrations of PBP8 rectally for 277 three days prior to DSS intake, during five days of DSS intake, and during a five day recovery with colon length reduction (39). We found that colon length did not differ significantly between 290 the PBP8 CsgA-TFF3 group and the healthy control group, suggesting that in situ CsgA-TFF3 291 production attenuated colonic inflammation caused by DSS. In comparison, the colitic control, 292 PBP8, and PBP8 wt-CsgA groups all had shorter colons ( Figure 6D ). 293 We also assessed the effects of bacterial administration on gut inflammation using 294 histology. Common histological characteristics of DSS induced colitis include immune cell 295 infiltration involving multiple tissue layers as well as loss of colonic crypts and epithelial 296 damage (40, 41). We employed a histological scoring system based on previously published 297 accounts (Table S2 ) (40-42). All of the groups that received DSS treatment had significantly 298 higher histopathology scores than the healthy control group, indicating more inflammatory 299 effects ( Figure 6E ). The histology score for the PBP8 CsgA-TFF3 group was the lowest of all the 300 groups that received DSS, though the difference was not quite significant according to our 301 scoring and statistics criteria. Images of the histology sections from the colitic control group 302 showed complete loss of crypt structure, goblet cell depletion, immune cell infiltration into the 303 lumen, and edema of the tissues around the colon, all of which reflect the severe inflammatory 304 effects of DSS treatment ( Figure 6F ). In contrast, tissue sections from mice treated with bacteria 305 showed some qualitative improvements, with better preservation of crypt structure. The PBP8
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CsgA-TFF3 group also showed lower inflammatory cell infiltration, less edema, and more intact 307 epithelium. One explanation for the histological similarity among the DSS treated groups could 308 be that the tissue sections were obtained 5 days after DSS treatment had stopped. Therefore, 309 natural healing processes could have obscured any quantitative differences in histopathology 310 between the groups that received DSS and bacteria. Anti-inflammatory effects of engineered EcN are associated with immunomodulation and barrier 323 function enhancement 324 In order to start probing the mechanism of the apparent protective effects of the PATCH system 325 with CsgA-TFF3, we analyzed gene expression and protein production profiles from colonic 326 tissue homogenates across the experimental groups. The DSS colitis model leads to several such 327 changes, including downregulation of genes associated with epithelial barrier function and 328 upregulation of genes associated with inflammatory signaling (43, 44) . With respect to tight 329 junction protein-1 (TJP-1), a.k.a. zona occludens-1 (ZO-1), the PBP8 CsgA-TFF3 group showed 330 significantly higher mRNA levels than the colitic control group ( Figure 7A ). This is in line with 331 the known functions of TFFs in mammalian hosts even though other markers of barrier function 332 associated with TFF bioactivity (occludin, claudin-2, and intestinal TFF3, Figure S6A -C) did not 333 show changes according to qRT-PCR analysis. Notably, the PBP8 wt-CsgA group also exhibited 334 high tjp-1 mRNA levels. This could the explained by known interactions between wt-CsgA and 335 toll-like receptor 2 (TLR2), which can indirectly lead to moderate increases in tjp-1 expression 336 (45, 46). Although the effects of TFF3 fusion to CsgA on its interaction with host receptors is not 337 clear form this work, it is possible that both domains could contribute to modulating local gene 338 expression.
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Matrix metalloproteinase-9 (MMP-9), whose function is to breakdown extracellular 340 matrix proteins in inflammatory environments, is upregulated during IBD and is an essential 341 mediator of tissue injury during DSS colitis. Blockade of MMP-9 has also been explored as a 342 clinical treatment for IBD (47). In our experiments, the colitic control and PBP8 control groups 343 showed elevated mmp9 mRNA levels compared to the healthy control group, while the PBP8
344
CsgA-TFF3 group showed significantly lower mmp9 expression ( Figure 7B ). Prostaglandin-345 endoperoxidase synthase 2 (PTGS-2), a.k.a. cyclooxygenase-2 (COX-2), showed similar results 346 to MMP-9, with the PBP8 CsgA-TFF3 group significantly lower than the colitic group, and 347 comparable with the healthy control group ( Figure 7C ). PTGS-2 is an enzyme whose production 348 is induced in the colon during active IBD (48). Its inhibition has also been investigated as an 349 anti-inflammatory treatment, and has ameliorated colitis in a murine DSS model (49). Similar to 350 the case of MMP-9, the PBP8 wt-CsgA group also showed reduced ptgs2 expression, which 351 likely reflects the known interactions of unmodified curli fibers with the gut epithelium observed 352 in this work and elsewhere (50).
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Finally, we used a parallelized ELISA assay (Luminex), to probe cytokine levels from 354 tissue homogenates obtained from mice at the experimental endpoint. We found that IL-6, IL- 
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Discussion
369
We have developed an engineered beneficial bacterium that produces a self-assembled matrix in 370 situ within the GI tract with programmable functions. Our engineering strategy (PATCH) 371 enabled the production of a modified curli fiber matrix with fused TFFs under physiological 372 conditions in a manner that does not appear to alter EcN's inherent lack of pathogenicity.
373
Administration of the engineered bacterium before, during, and after the induction of colitis in 374 mice led to amelioration of inflammation and a reduction in Th17 responses in the colon. The 375 protective effect of PATCH with CsgA-TFF3 also correlated with enhanced mucosal barrier 376 function and is correlated with a reduction in the expression of inflammatory cytokines and 377 enzymes in colonic tissues. Although more detailed studies will be required to rigorously 378 confirm the mechanism of these effects, results from the genetic and biochemical analyses we 379 performed were in line with previous accounts of trefoil factor bioactivity, which includes 380 immunomodulation, the promotion of epithelial restitution, and upregulation of tight junction 381 proteins (Figure 1) (20, 21) . 382 Ongoing work in the lab is focused on improving the PATCH system in order to make it more 383 suitable for clinical deployment. In the experiments described here, antibiotics and small 384 molecule inducers were fed to the mice in order to maintain the plasmid's stability in the 385 modified EcN strains and induce curli production, respectively. The antibiotics alter the gut 386 microbiome significantly (52). To address this issue, second generation PATCH systems should 387 be engineered with stable plasmid systems that do not require antibiotics that have been reported 388 on extensively elsewhere (33, 53, 54) . Although we demonstrated that oral administration was a 389 viable approach to establishing a detectable and stable population of engineered EcN strains in 390 the murine lower intestine, we ultimately opted for rectal administration to colocalize the 391 bacteria near diseased areas and demonstrate efficacy. However, human IBD pathology can be 392 spread across the colon and parts of the small intestine. Furthermore, E. coli is similarly localized 393 in humans, and is known to proliferate at sites of inflammation (55). Therefore, either oral or 394 rectal delivery may be relevant for other models of IBD or in humans. We also recognize that the 395 curli fibers themselves are not a "blank slate" material in that CsgA already has numerous known 396 interactions with host cells and tissues that could confound the effects of the displayed domains 397 (46, 50, 56). While this may or may not impede further development of PATCH with curli fibers 398 as a scaffold, we know that the biosynthetic machinery dedicated to curli secretion can tolerate a 399 wide range of heterologous proteins (57). We are therefore in the process of exploring other 400 combinations of scaffolding proteins and bioactive domains that can be secreted through the curli 401 (a.k.a. "Type VIII") pathway to circumvent these confounding effects and probe different 402 therapeutic modalities.
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Effective treatments for IBD with fewer undesirable side effects are a pressing medical need.
404
Our platform has several features that make it potentially useful for clinical applications, The design and construction of the synthetic curli operon encoding plasmids are described in 420 detail elsewhere (24). Briefly, a pBbB8k plasmid backbone contains the genes csgBA*CEFG as 421 a single cistron, controlled by the araBAD promoter, where A* indicates either wild-type or 422 chimeric CsgA. Gene fragments encoding 6xHis tag modified TFF1-3 domains were cloned into 423 these vectors to create pBbB8k-CsgA-TFF1, pBbB8k-CsgA-TFF2, and pBbB8k-CsgA-TFF3 (see supplementary document for CsgA fusion sequences and Figure S7 for pBbB8k-wt-CsgA 425 plasmid map). The list of bacteria strains and plasmids can be found in Table S3 . The list of 426 reagents with distributers can be found in supplementary reagent list document. The details of in 427 vitro curli expression can be found in additional materials and methods. 
Gene expression analysis by qRT-PCR 563
RNAlater-stabilized tissues were subjected to total RNA extraction using the TissueLyser LT 564 and RNeasy plus mini kit in accordance with the manufacturer's protocol. RNA samples were 565 eluted with 100 µL RNase free water provided from the kit. Following the elution, the 566 concentration of RNA was determined by spectroscopy using the Nanodrop 2000c. 10 ng of 567 RNA was analyzed using specific primers for each gene of interest (Table S4) analyzed using two-way ANOVA following by Dunnett's multiple comparison. An associated 583 probability (p value) of less than 0.05 was considered significant and given one star, whereas the 584 p < 0.01 was given two stars, p < 0.001 was given three stars, p < 0.0001 was given four stars, 585 and p > 0.05 was given "ns" accordingly. Table S2 for details), at endpoint from two 
